BERLIN & CARSON CITY, Nev.–(BUSINESS WIRE)–MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, published today its financial results for the first half of 2016, ending on June 30, 2016, and operative highlights. Operative Highlights: Brain Cancer NanoTherm(TM) Therapy at MagForce AG In Europe, MagForce AG is continuing to expand the commercialization phase of its valuable NanoTherm(TM) ther